Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory MM

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA(2023)

引用 0|浏览14
暂无评分
关键词
daratumumab-based,second-line
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要